Non-Hodgkin Lymphoma | Specialty

The GALLIUM Study in Follicular Lymphoma

July 9th 2019

The National LymphoCare Study in Follicular Lymphoma

July 9th 2019

Frontline Treatment Regimens in Follicular Lymphoma

July 9th 2019

Initiating Therapy in Follicular Lymphoma

July 9th 2019

Risk Assessment for Patients With Follicular Lymphoma

July 9th 2019

Optimal Strategies to Help Diagnose Follicular Lymphoma

July 9th 2019

Expert Sorts Through Treatment Strategies in Follicular Lymphoma

July 2nd 2019

Chaitra S. Ujjani, MD, discusses the various therapeutic classes and agents that are showing the most promise in the field of follicular lymphoma.

Dr. Lugtenburg on Maintenance Rituximab in DLBCL

June 20th 2019

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.

Optimal Upfront Lenalidomide/R-CHOP Use Remains Puzzle in DLBCL

June 20th 2019

Patients with activated B-cell-type diffuse large B-cell lymphoma with a poor prognosis may benefit from frontline treatment with lenalidomide plus standard R-CHOP, according to subgroup data from the phase III ROBUST trial presented at the 2019 International Conference on Malignant Lymphoma.

Dr. Vose on Acalabrutinib/Pembrolizumab Combo in DLBCL

June 19th 2019

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

FDA Approves Polatuzumab Vedotin for DLBCL

June 10th 2019

The FDA has granted an accelerated approval to polatuzumab vedotin (Polivy) for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Pipeline Updates Advance Paradigms Across Lymphomas

May 31st 2019

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

FDA Grants Copanlisib Breakthrough Designation for MZL

May 30th 2019

The FDA has granted copanlisib (Aliqopa) a breakthrough therapy designation for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least 2 prior therapies.

Dr. LaCasce Discusses the FDA Approval of Lenalidomide/Rituximab in Non-Hodgkin Lymphoma

May 28th 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the FDA approval of lenalidomide (Revlimid) and rituximab (Rituxan; R2) in non-Hodgkin lymphoma.

FDA Approves Lenalidomide/Rituximab for Indolent Non-Hodgkin Lymphoma

May 28th 2019

The FDA has approved the R2 regimen of lenalidomide plus rituximab for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

Frontline Lenalidomide/R-CHOP Combo Misses Primary Endpoint in DLBCL

April 26th 2019

The combination of lenalidomide (Revlimid) with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; R2-CHOP) did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

April 17th 2019

Daratumumab was associated with low overall response rates in patients with relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, missing the primary endpoint of a phase II trial published in Clinical Lymphoma, Myeloma & Leukemia.1

Lenalidomide/Rituximab Data Published as FDA Weighs Non-Hodgkin Lymphoma Approval

April 9th 2019

The R2 regimen of lenalidomide plus rituximab significantly reduced the risk of disease progression or death compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to results from the pivotal phase III AUGMENT trial.

Dr. Shaughnessy Discusses Unanswered Questions in DLBCL

April 4th 2019

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses unanswered questions in the field of diffuse large B-cell lymphoma (DLBCL).

Dr. Kaplan on a Study With Combination Immune Macrophage Checkpoint Blockade in Lymphoma

March 6th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib study with combination immune macrophage checkpoint blockade in indolent lymphoma.